Expression, Crystallization, and Three-dimensional Structure of the Catalytic Domain of Human Plasma Kallikrein-Reference-Cited by-同舟云学术

Expression, Crystallization, and Three-dimensional Structure of the Catalytic Domain of Human Plasma Kallikrein

Published:2005-12 Issue:49 Volume:280 Page:41077-41089
ISSN:0021-9258
Container-title:Journal of Biological Chemistry
language:en
Short-container-title:Journal of Biological Chemistry

Author:

Tang Jie,Yu Christine Luong,Williams Steven R.,Springman Eric,Jeffery Douglas,Sprengeler Paul A.,Estevez Alberto,Sampang Jun,Shrader William,Spencer Jeff,Young Wendy,McGrath Mary,Katz Bradley A.

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry

Reference71 articles.

1. Der Nachweis eines Kreislaufhormons in der Pankreasdrüse. (IV. Mitteilung über dieses Kreislaufhormon.)

2. Evidence for a New Plasma Thromboplastin Factor I. Case Report, Coagulation Studies and Physicochemical Properties

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling therapeutic frontiers: DON/DRP-104 as innovative Plasma kallikrein inhibitors against carcinoma-associated hereditary angioedema shocks - a comprehensive molecular dynamics exploration;Cell Biochemistry and Biophysics;2024-06

2. Unveiling Therapeutic Frontiers: DON/DRP-104 as Innovative Plasma Kallikrein Inhibitors Against Carcinoma-Associated Hereditary Angioedema Shocks - A Comprehensive Molecular Dynamics Exploration;2024-01-15

3. STAR-0215 is a Novel, Long-Acting Monoclonal Antibody Inhibitor of Plasma Kallikrein for the Potential Treatment of Hereditary Angioedema;Journal of Pharmacology and Experimental Therapeutics;2023-08-29

4. Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On-Demand Treatment for Hereditary Angioedema;Journal of Medicinal Chemistry;2022-10-17

5. Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On-Demand Treatment for Hereditary Angioedema;J MED CHEM;2022